Y-mAbs Therapeutics is a startup based in the United States, most recent round Acquired, 1 tracked investor.
Y-mAbs Therapeutics is a startup based in the United States. Y-mAbs Therapeutics has been acquired. Brouky records 1 investor associated with the company.
Y-mAbs Therapeutics develops and commercializes radioimmunotherapy and antibody-based oncology therapies; its marketed product DANYELZA (naxitamab) is indicated for relapsed or refractory high‑risk neuroblastoma. The company focuses on developing targeted biologic treatments for difficult-to-treat cancers.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.